Skip to content

Microcirculation During Haemodialysis

Sublingual Microcirculatory Flow Measurements During Haemodialysis in Relation to Blood Volume Change

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01396980
Enrollment
8
Registered
2011-07-19
Start date
2011-09-30
Completion date
2012-02-29
Last updated
2012-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication of Hemodialysis

Keywords

hemodialysis, intensive care, microcirculation

Brief summary

* SDF is validated by measuring changes in microcirculation in sepsis patients with MOF (Boerma studies). * SDF is validated by measuring changes in microcirculation in stable chronic hemodialysis patients (NDT 2009 Bemelmans). * Ultrafiltration in stable chronic hemodialysis leads to a decrease in sublingual microcirculatory flow (NDT 2009 Bemelmans). * Trendelenburg position improves the sublingual microcirculatory flow at the end of hemodialysis treatment (NDT 2009 Bemelmans). * Hemodialysis with ultrafiltration leads to a significant reduction of myocardial perfusion and cardiac output (NDT 2009 Dasselaar) * Cardiac output measurement during dialysis is not practical. * BVM is a validated method for hypotension due to ultrafiltration to prevent the amount of ultrafiltration online change based on the measured haemoconcentration (ref Dasselaar et al NDT 2005). * BCM is a validated measurement to the dry weight in hemodialysis patients measured by a bioimpedance technique (NDT Passauer et al 2009).

Detailed description

The search for an optimal method of ultrafiltration with minimal hypoperfusion of vital organs. * Stabile hemodialysis patients with dialysis dependancy for more than 3 months, with adequate access * Study duration 3 weeks * Number of hemodialysis treatment for purposes of study: 3 * Timing hemodialysis treatments for Study session Monday or Tuesday after the weekend (randomized design in the sessions) * session a: 5 hours total duration: 4 hours HD without UF followed by 1 hour GUF * Session b: 4 hours total duration: 4 hours HD with UF * session c: 4 hours total duration: 4 hours HD with UF and BVM * UF is determined by actual target weight. * Measurements during sessions: * In each session in advance: blood pressure, pulse, weight, BCM, laboratory tests (Hb, Hct, Na, K, urea, creatinine, calcium, albumin, phosphate, nt-proBNP, troponin T, CRP) * During each session at t = 0, t = 1 hour, t =2 hours and t = 4 hours: SDF, blood pressure, pulse, UF at that time, UF rate at that time * End each session: blood pressure, pulse, weight, BCM, laboratory tests (Hb, Hct, Na, K, urea, creatinine, calcium, albumin, phosphate, nt-proBNP, troponin T, CRP)

Interventions

None listed

Sponsors

Frisius Medisch Centrum
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* dialysis patient * age \> 18 * informed consent

Exclusion criteria

* no adequate access * instable hemodynamics

Design outcomes

Primary

MeasureTime frame
Difference between sublingual microvascular flow index between 2 types of ultrafiltration3 weeks

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026